Citalopram
Product Images NDC 61919-390

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Citalopram (NDC 61919-390). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Direct Rx, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Label)

Citalopram 40 mg tablet bottle label from Direct Rx, containing 30 tablets. The label indicates the generic for Celexa and that each tablet contains citalopram hydrobromide equivalent to 40 mg citalopram. The label includes lot, product number, discard date, and packaging location in Alpharetta, GA, along with usage and storage warnings.*

FDA Label Image

Image Description (Molecule)

Chemical structure of Citalopram, showing its molecular formula C20H22BrFN2O and molecular weight of 405.35, with visible atom groups and bonds including nitrogen (N), bromine (Br), fluorine (F), and oxygen (O).*

FDA Label Image

Image Description (Picture)

FDA Label Image

Image Description (Picture2)

FDA Label Image

Image Description (Table1 1)

A data table presenting information related to patients treated, with several rows and columns. The exact numerical details and column headers are not fully visible in the cropped image.*

FDA Label Image

Image Description (Table1)

A data table titled 'TABLE 1' displaying the drug-placebo difference in the number of cases of suicidality per 1000 patients by age range. It shows increased cases compared to placebo in patients under 18 (14 additional cases) and ages 18-24 (5 additional cases), and decreased cases in ages 25-64 (1 fewer case) and 65 or older (6 fewer cases).*

FDA Label Image

Image Description (Table2 1)

A data table showing percentages of reported adverse reactions for symptoms including insomnia, somnolence, and agitation, with columns indicating different frequency counts or groups.*

FDA Label Image

Image Description (Table2)

A data table titled 'Adverse Events Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled, Depression Trials.' It compares the percentage of patients discontinuing due to adverse events between Citalopram (N=1063) and placebo (N=446), across body systems including general, gastrointestinal disorders, and central and peripheral nervous system disorders with specific adverse events such as asthenia, nausea, dry mouth, vomiting, and dizziness.*

FDA Label Image

Image Description (Table3 1)

A data table listing selected adverse reactions categorized by system organ classes such as General, Musculoskeletal, Psychiatric, and Respiratory System Disorders. It includes percentages representing the incidence of specific symptoms like fatigue, fever, arthralgia, somnolence, insomnia, anxiety, and respiratory infections in different columns.*

FDA Label Image

Image Description (Table3 2)

A data table presenting the frequency of urogenital side effects, specifically Ejaculation Disorder and Impotence, with percentages for two groups or conditions shown as 6% vs. 1% and 3% vs. less than 1%, respectively.*

FDA Label Image

Image Description (Table3)

A data table titled 'Treatment-Emergent Adverse Events: Incidence in Placebo-Controlled Clinical Trials' comparing the percentage of patients reporting adverse events for Citalopram HBr (N=1063) and placebo (N=446). It lists body system/adverse events including autonomic nervous system disorders (dry mouth, sweating increased), central & peripheral nervous system disorders (tremor), and gastrointestinal disorders (nausea, diarrhea, dyspepsia, vomiting, abdominal pain) with corresponding percentages for each group.*

FDA Label Image

Image Description (Table4)

A data table comparing sexual side effects rates between Citalopram and placebo treatments in males. It lists percentages for abnormal ejaculation, decreased libido, and impotence among 425 males taking Citalopram and 194 males taking placebo, specifying that all effects are in males only.*

FDA Label Image

Image Description (Table5 1)

A text panel containing information about Citalopram, mentioning hydrobromide or escitalopram oxalate and including Lexapro.*

FDA Label Image

Image Description (Table5)

This text panel advises that patients taking citalopram tablets should avoid other medicines containing citalopram to prevent duplication. It is a medication usage advisory relevant for users of citalopram products.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.